Abstract
Introduction: The outcome of patients with metastatic colorectal cancer (mCRC) has improved significantly in the last few decades. Metastatic colorectal cancer is a highly heterogenous cancer. Beyond second line chemotherapy, treatment decisions are often based on molecular testing.
Method: In this narrative review, we provide a comprehensive summary of data from key clinical trials and discuss how to integrate these agents into the current treatment landscape of metastatic colorectal cancer.
Expert Opinion: In the era of precision medicine, molecular testing plays an increasingly important role in the management of mCRC. Efforts need to be made to target treatment based on molecular test results.
| Original language | English |
|---|---|
| Pages (from-to) | 219-227 |
| Number of pages | 9 |
| Journal | Expert Review of Anticancer Therapy |
| Volume | 24 |
| Issue number | 5 |
| Early online date | 3 Apr 2024 |
| DOIs | |
| Publication status | Published - May 2024 |
Keywords
- biomarkers
- immunotherapy
- Metastatic colorectal cancer
- refractory disease
- targeted therapy
